DÄ internationalArchive43/2006Risk of Myocardial Infarction Following Coronary Stent Implantation without Adequate Clopidogrel Treatment

Review article

Risk of Myocardial Infarction Following Coronary Stent Implantation without Adequate Clopidogrel Treatment

Dtsch Arztebl 2006; 103(43): A-2863

Silber, S; Böhm, M; Gottwik, M; Borggrefe, M; Dietz, R

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Silber S, Albertsson P, Aviles FF et al.: Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European society of cardiology. Eur Heart J, 2005; 26: 804–47. MEDLINE
2. Leon MB, Baim DS, Popma JJ et al.: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators (STARS). N Engl J Med, 1998; 339: 1665–71. MEDLINE
3. CAPRIE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996; 348: 1329–39. MEDLINE
4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001; 345: 494–502. MEDLINE
5. Mehta SR, Yusuf S, Peters RJ et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001; 358: 527–33. MEDLINE
6. Diener HC, Bogousslavsky J, Brass LM et al.: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet, 2004; 364: 331–7. MEDLINE
7. Bhatt DL, Fox KA, Hacke W et al.: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med, 2006; 354: 1706–17. MEDLINE
8. Hall P, Nakamura S, Maiello L et al.: A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation, 1996; 93: 215–22. MEDLINE
9. Schömig A, Neumann FJ, Kastrati A et al.: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med, 1996; 334: 1084–9. MEDLINE
10. Bertrand ME, Legrand V, Boland J et al.: Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation, 1998; 98: 1597–603. MEDLINE
11. Urban P, Macaya C, Rupprecht HJ et al.: Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation, 1998; 98: 2126–32. MEDLINE
12. Cutlip DE, Baim DS, Ho KK et al.: Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation, 2001; 103: 1967–71. MEDLINE
13. Silber S, von Rottkay P, Lössl P et al.: Sicherheit und Durchführbarkeit der intrakoronaren Brachytherapie mit dem Novoste™-System im Rahmen von internationalen Multicenter-Studien. Z Kardiol, 2000; 89: 323–9. MEDLINE
14. Serruys PW, Kutryk MJ, Ong AT: Coronary-artery stents. N Engl J Med, 2006; 354: 483–95. MEDLINE
15. Silber S: Antiproliferativ beschichtete Stents und intrakoronare Brachytherapie: Gemeinsamkeiten und Unterschiede. Z Kardiol, 2002; 91: 443–57. MEDLINE
16. Waksman R, Ajani AE, Pinnow E et al.: Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation, 2002; 106: 776–8. MEDLINE
17. Iakovou I, Schmidt T, Bonizzoni E et al.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA, 2005; 293: 2126–30. MEDLINE
18. McFadden EP, Stabile E, Regar E et al.: Late thrombosis in drugeluting coronary stents after discontinuation of antiplatelet therapy. Lancet, 2004; 364: 1519–21. MEDLINE
19. Feres F, Costa JR Jr., Abizaid A: Very late thrombosis after drugeluting stents. Catheter Cardiovasc Interv, 2006; 68: 83–8. MEDLINE
20. Müller I, Seyfarth M, Rüdiger S et al.: Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart, 2001; 85: 92–3. MEDLINE
21. Pfisterer ME: BASKET LATE Trial. late breaking trials, Jahrestagung des American College of Cardiology, ACC, Atlanta, März, 2006.
22. Moreno R, Fernandez C, Hernandez R et al.: Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol, 2005; 45: 954–9. MEDLINE
23. Cosgrave J, Agostoni P, Ge L et al.: Clinical outcome following aleatory implantation of Paclitaxel-eluting or sirolimus-eluting stents in complex coronary lesions. Am J Cardiol, 2005; 96: 1663–8. MEDLINE
24. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al.: Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol, 2006; 97: 38–43. MEDLINE
25. Aoki J, Serruys PW, van Beusekom H et al.: Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol, 2005; 45: 1574–9. MEDLINE
e1. van Buuren F, Horstkotte D: 21. Bericht über die Leistungszahlen der Herzkatheterlabore in der Bundesrepublik Deutschland. Clin Res Cardiol, 2006; 95: 383–87. MEDLINE
e2. Silber S: "Off-Label" Verschreibung von Clopidogrel nach Stentimplantation: verzichtbar oder zwingend? Herz, 2003; 28: 65–71. MEDLINE
e3. KVB: Arzneimittel im Blickpunkt: Clopidogrel. http://www.kvb.de/servlet/PB/show/1006375/Arzneimittel-im-Blickpunkt-2-2005--Beilage_AAI_RTM.pdf, 2005.
e4. Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ: Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med, 2005; 352: 238–44. MEDLINE
e5. IQWiG: Berichtsplan zum Bericht: Clopidogrel versus Acetylsalicylsäure in der Sekundärprophylaxe vaskulärer Erkrankungen [Auftrag A04-01A] http://www.iqwig.de/de/auftraege/arzneimittel_/Auftragsliste.html, 2005.
e6. IQWiG: Kombination von Clopidogrel und Acetylsalicylsäure versus Monotherapie mit Acetylsalicylsäure beim akuten Koronarsyndrom ohne ST-Hebungs-Myokardinfarkt [A04/01-B] http://www.iqwig.de/de/auftraege/arzneimittel_/Auftragsliste.html, 2005.
e7. Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R: Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess, 2004; 8: iii–iv, 1–196. MEDLINE
e8. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation, 2000; 102: 624–9. MEDLINE
e9. Müller C, Büttner HJ, Petersen J, Roskamm H: A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation, 2000; 101: 590–3. MEDLINE
e10. Taniuchi M, Kurz HI, Lasala JM: Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation, 2001; 104: 539–43. MEDLINE
e11. Calver AL, Blows LJ, Harmer S, Dawkins KD, Gray HH, Morgan JH, Simpson IA: Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents. Am Heart J, 2000; 140: 483–91. MEDLINE
e12. Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S, Maida R, Collins M, Kreps E, Moses JW: Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation, 1999; 99: 2364–66. MEDLINE
e13. Berger PB: Clopidogrel instead of ticlopidine after coronary stent placement: is the switch justified? Am Heart J, 2000; 140: 354–8. MEDLINE
e14. Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Moses JW, Dangas G, Taniuchi M, Lasala JM, Holmes DR, Ellis SG, Topol EJ: Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol, 2002; 39: 9–14. MEDLINE
e15. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL: What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J Am Coll Cardiol, 2005; 45: 941–6. MEDLINE
e16. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ: A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet, 2004; 364: 583–91. MEDLINE
e17. Takano M, Mizuno K: Late coronary thrombosis in a sirolimuseluting stent due to the lack of neointimal coverage. Eur Heart J, 2006; 27: 1133. MEDLINE
e18. Ge L, Airoldi F, Iakovou I, Cosgrave J, Michev I, Sangiorgi GM, Montorfano M, Chieffo A, Carlino M, Corvaja N, Colombo A: Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation. J Am Coll Cardiol, 2005; 46: 613–20. MEDLINE
e19. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS, Ho KK, Cohen DJ, Garcia LA, Cutlip DE, Carrozza JP Jr.: Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation, 2004; 109: 1930–2. MEDLINE
e20. Silber S, Colombo A, Banning A, Hauptmann KE, Drzewiecki J, Grube E, Koglin J, Russel ME: TAXUS II: Prolonged Clinical Follow-Up after Thienopyridine Withdrawal. JACC (abstr), 2005; Suppl A, 45: 34A.
e21. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Krumholz HM, Cohen DJ: Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation, 2006; 113: 2803–9. MEDLINE
e22. Wenaweser P, Rey C, Eberli FR, Togni M, Tuller D, Locher S, Remondino A, Seiler C, Hess OM, Meier B, Windecker S: Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J, 2005; 26: 1180–7. MEDLINE
e23. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G: Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation, 2005; 111: 2099–106. MEDLINE
e24. von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A: Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation, 2005; 112: 2946–50. MEDLINE
e25. Steinhubl SR, Berger PB, Mann JT, 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002; 288: 2411–20. MEDLINE
e26. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Büttner HJ, Neumann FJ: Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation, 2005; 111: 2560–4. MEDLINE
e27. Kandzari DE, berger PB, Kastrati A, Steinhubl S, Mehilli J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Dirschinger J, Schömig A: Influence of Treatment Duration With a 600-mg Dose of Clopidogrel Before Percutaneous Coronary Revascularization. JACC, 2004; 44: 2133–6. MEDLINE
e28. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med, 2005; 352: 1179–89. MEDLINE
e29. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Lewis BS, Murphy SA, McCabe CH, Braunwald E: Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA, 2005; 294: 1224–32. MEDLINE
e30. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial (COMMIT/CCS-2). Lancet, 2005; 366: 1607–21. MEDLINE
e31. Beinart SC, Kolm P, Veledar E, Zhang Z, Mahoney EM, Bouin O, Gabriel S, Jackson J, Chen R, Caro J, Steinhubl S, Topol E, Weintraub WS: Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol, 2005; 46: 761–9. MEDLINE
e32. Smith SC Jr., Feldman TE, Hirshfeld JW Jr., Jacobs AK, Kern MJ, King SB, 3rd, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Smith SC Jr., Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B: ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol, 2006; 47: 216–35. MEDLINE
e33. Wenaweser P, Dorffler-Melly J, Imboden K, Windecker S, Togni M, Meier B, Haeberli A, Hess OM: Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol, 2005; 45: 1748–52. MEDLINE
e34. Wang TH, Bhatt DL, Topol EJ: Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J, 2006; 27: 647–54. MEDLINE
e35. Mason PJ, Jacobs AK, Freedman JE: Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol, 2005; 46: 986–93. MEDLINE
e36. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US: Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol, 2005; 46: 1827–32. MEDLINE
e37. Nguyen TA, Diodati JG, Pharand C: Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol, 2005; 45: 1157–64. MEDLINE
e38. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF, Kleiman NS: Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol, 2006; 47: 27–33. MEDLINE
e39. Manor SM, Guillory GS, Jain SP: Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting. Pharmacotherapy, 2004; 24: 664–7. MEDLINE
e40. Haj M, Dasani H, Kundu S, Mohite U, Collins PW: Acquired haemophilia A may be associated with clopidogrel. BMJ, 2004; 329: 323. MEDLINE